Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Inhibition of RANKL: a new approach to the treatment of osteoporosis

Doggrell, SA (2006). Inhibition of RANKL: a new approach to the treatment of osteoporosis. Expert Opinion on Pharmacotherapy,7(8):1097-1100.

Document type: Journal Article
Citation counts: Scopus Citation Count Cited 2 times in Scopus Article | Citations

Google Scholar Search Google Scholar

Title Inhibition of RANKL: a new approach to the treatment of osteoporosis
Author Doggrell, SA
Journal Name Expert Opinion on Pharmacotherapy
Publication Date 2006
Volume Number 7
Issue Number 8
ISSN 1465-6566   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-33745447763
Start Page 1097
End Page 1100
Total Pages 4
Publisher Informa Healthcare
HERDC Category C1 - Journal Article (DEST)
Abstract Osteoporosis affects > 10 million people in the US. Although there are a range of drugs available to treat osteoporosis, adherence to these agents is poor, leaving patients at risk of fracture. Receptor activator of nuclear-kappa B ligand (RANKL) is essential for the function of the bone-resorbing osteoclasts. Denosumab is a humanised monoclonal antibody to RANKL that can be administered subcutaneously every 3 or 6 months. With this protocol, denosumab increased bone mineral density in the lumbar spine and total hip of postmenopausal women with osteoporosis over 1 year. This confirms that inhibition of RANKL is a new and potentially useful approach to the treatment of osteoporosis. The long-term safety of denosumab, and the effect of denosumab on the incidence of fractures, needs to be evaluated, especially as there is, as yet, no indication that denosumab decreases the incidence of fractures. Comparative studies with denosumab, once-weekly alendronate and once-yearly zoledronate, evaluating their effects on bone mineral density and fractures and the degree of adherence, also need to be considered.
Keywords alendronate
bone mineral density
denosumab
postmenopausal osteoporosis
rankl
parathyroid-hormone
postmenopausal women
double-blind
alendronate
DOI http://dx.doi.org/10.1517/14656566.7.8.1097   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 31 Abstract Views  -  Detailed Statistics
Created: Wed, 28 Nov 2007, 14:16:08 CST